Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 3
1962 1
1963 1
1976 1
1983 3
1985 3
1986 1
1987 3
1988 2
1990 2
1991 1
1992 3
1993 3
1994 2
1996 1
1997 2
1998 2
1999 4
2000 1
2001 1
2002 3
2003 6
2004 1
2005 3
2006 2
2007 1
2008 2
2009 8
2010 7
2011 6
2012 4
2013 4
2014 6
2015 10
2016 6
2017 5
2018 8
2019 5
2020 15
2021 12
2022 14
2023 14
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, McTigue K, Thicklin F, Felker GM, Ginde AA, Bramante CT, Slandzicki AJ, Gabriel A, Shah NS, Lenert LA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Wilder R, Wilson S, Shenkman E, Hernandez AF; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Naggie S, et al. JAMA. 2022 Oct 25;328(16):1595-1603. doi: 10.1001/jama.2022.18590. JAMA. 2022. PMID: 36269852 Free PMC article. Clinical Trial.
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Slandzicki AJ, Lim SC, Cohen J, Kavtaradze D, Amon AP, Gabriel A, Gentile N, Felker GM, Jayaweera D, McCarthy MW, Sulkowski M, Rothman RL, Wilson S, DeLong A, Remaly A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Thicklin F, Hanna GJ, Ginde AA, Castro M, McTigue K, Shenkman E, Hernandez AF; Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Naggie S, et al. JAMA. 2023 Mar 21;329(11):888-897. doi: 10.1001/jama.2023.1650. JAMA. 2023. PMID: 36807465 Free PMC article.
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.
Boulware DR, Lindsell CJ, Stewart TG, Hernandez AF, Collins S, McCarthy MW, Jayaweera D, Gentile N, Castro M, Sulkowski M, McTigue K, Felker GM, Ginde AA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Thicklin F, Wilder R, Wilson S, Shenkman E, Naggie S; ACTIV-6 Study Group and Investigators. Boulware DR, et al. N Engl J Med. 2023 Sep 21;389(12):1085-1095. doi: 10.1056/NEJMoa2209421. N Engl J Med. 2023. PMID: 37733308 Free PMC article. Clinical Trial.
Anaesthetic management of people with multiple sclerosis.
Dubuisson N, de Maere d'Aertrijcke O, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G, Verma V, Docquier MA. Dubuisson N, et al. Among authors: marta m. Mult Scler Relat Disord. 2023 Dec;80:105045. doi: 10.1016/j.msard.2023.105045. Epub 2023 Oct 11. Mult Scler Relat Disord. 2023. PMID: 37866022 Free article. Review.
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S, Holden DW, Marta M, Mathews J, Turner BP, Baker D, Schmierer K. Allen-Philbey K, et al. Among authors: marta m. Ther Adv Neurol Disord. 2023 Nov 10;16:17562864231200627. doi: 10.1177/17562864231200627. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37954917 Free PMC article.
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Stewart TG, Rebolledo PA, Mourad A, Lindsell CJ, Boulware DR, McCarthy MW, Thicklin F, Garcia Del Sol IT, Bramante CT, Lenert LA, Lim S, Williamson JC, Cardona OQ, Scott J, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Rothman RL, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Stewart TG, et al. JAMA. 2023 Dec 26;330(24):2354-2363. doi: 10.1001/jama.2023.23363. JAMA. 2023. PMID: 37976072 Free PMC article.
Protecting people with multiple sclerosis through vaccination.
Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Mathews J, Lambourne J, Marta M, Turner B, Gnanapavan S, Dobson R, Schmierer K, Giovannoni G. Reyes S, et al. Among authors: marta m. Pract Neurol. 2020 Dec;20(6):435-445. doi: 10.1136/practneurol-2020-002527. Epub 2020 Jul 6. Pract Neurol. 2020. PMID: 32632038 Review.
186 results